GSK_Annual_Report_2021

Notes to the Consolidated Financial Statements for the year ended March 31, 2021 (contd.) Financial Statements GlaxoSmithKline Pharmaceuticals Limited 190 ( ` in lakhs) As at March 31, 2021 As at March 31, 2020 Note 8 : Other non-current assets Capital advances 2,87.24 2,84.25 Less : Allowance for doubtful advances (2,83.17) (2,83.17) 4.07 1.08 Balances with Government Authorities 15,86.97 11,88.77 Sundry Deposits 31,23.66 32,58.25 Others 3,02.02 3,03.26 50,16.72 47,51.36 Note 9 : Inventories (at lower of cost or net realisable value) Raw and Packing materials (includes in-transit as on March 31, 2021: ` 9,06.49 lakhs; March 31, 2020 ` Nil) 100,34.63 76,47.89 Work-in-progress 1,30.12 30,72.62 Finished goods 127,87.81 92,38.26 Stock-in-trade (includes in-transit as on March 31, 2021: ` 17,11.20 lakhs; March 31, 2020 ` 23,20.70 lakhs) 313,38.13 280,02.46 Stores and spares 3,79.12 3,41.99 546,69.81 483,03.22 Note 10 : Trade receivables Unsecured, Considered good 215,60.46 99,80.12 Receivables which have significant increase in Credit Risk (Refer Note 48 C) 20,07.07 18,01.02 Less : Allowance for doubtful receivables (20,07.07) (18,01.02) 215,60.46 99,80.12 During the year ended March 31, 2021 the Group has created additional allowance for doubtful debts of ` 2,06.05 lakhs (net) (Previous Year: ` 2,74.08 lakhs). ( ` in lakhs) As at March 31, 2021 As at March 31, 2020 Note 11 : Cash and cash equivalents Balances with Banks: Current account 206,11.92 35,39.21 Term deposits with original maturity period of less than three months 199,07.00 6,00.00 Cheques on hand - 63,41.94 405,18.92 104,81.15